Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | CA9 | Q16790 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA7 | P43166 | 3/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048798 | 0.89 | CA1 (0.64) | CA2CA9CA1CA7CA14 | |
| SCHEMBL3045923 | 0.86 | CA1 (0.72) | CA2CA9CA1CA7CA14 | |
| SCHEMBL3054722 | 0.85 | MAPK1 (0.65) | CA2CA9CA1CA7CA14 | |
| SCHEMBL3056638 | 0.83 | PDE4B (0.65) | CA2CA9CA1CA7CA14 | |
| SCHEMBL3049295 | 0.81 | KDM4E (0.64) | CA2CA9CA1CA7CA14 | |
| SCHEMBL10350881 | 0.80 | CA7 (0.53) | CA2CA9CA1CA7CA14 | |
| SCHEMBL3055432 | 0.78 | CA9 (0.61) | CA2CA9CA1CA7CA14 | |
| SCHEMBL3064371 | 0.76 | CA9 (0.76) | CA2CA9CA7KMT2AMEN1 | |
| SCHEMBL3041866 | 0.74 | KMT2A (0.62) | MAPK1KMT2AMEN1ABCB1ALDH1A1 | |
| SCHEMBL3057847 | 0.73 | MAPK1 (0.62) | CA2CA9CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | claimed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| EP-2155192-B1 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LTD (GB) | 2016-09-28 | — | — | EP | disclosed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | CA2 1077/4885CA9 1002/4885CA1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.